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Cancer is a major cause of global disease-related mortality, and a well-recognized
health-care problem in developed countries in the West (US and Europe).
1 In
contrast to other leading causes of disease-related death such as heart disease and
stroke, the overall mortality rate due to cancer has not significantly improved over
the past thirty years.
2 In Asia, overall rates of cancer incidence are still compa-
ratively low compared to the West for major malignancies such as breast, colon
and prostate cancer.
3 However, the number of Asian patients diagnosed with
cancer is expected to dramatically rise in coming years. For example, in Singapore,
the breast cancer rate has increased by more than 25% over the past five years,
4
and in South Korea the proportion of colon cancers compared to all cancers has
almost doubled in the past twenty years, from 6% to 11%.
5 Reasons for the rapid
escalation of cancer in Asia include changes in lifestyle, dietary habits, and
increases in the average age of Asian populations.
3 In addition to cancers commonly
observed in both Eastern and Western countries, several malignancies such as
liver cancer (hepatocellular carcinoma, HCC), nasopharyngeal carcinoma and
stomach cancer (gastric cancer) are also known to occur far more frequently in
Asian countries.
3 The pathogenesis of these cancers has been largely linked to
exposures of Asian populations to potential carcinogens or infectious agents, such
as hepatitis and Epstein-Barr viruses for HCC and NPC respectively, or H. pylori
for gastric cancer.
6
Current epidemiological data indicates that the top three causes of global cancer
mortality are currently lung cancer, stomach cancer, and liver cancer.
1 The dismal
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THE RISING PROBLEM OF CANCER IN ASIAprognosis of these cancers, often associated with overall 5-
year survival rates of < 20%, can be ascribed to several
reasons. First, there is currently no effective screening
methodology to detect these cancers at early disease
stages, leading to most patients presenting with advanced
stage disease, which is traditionally associated with poor
prognosis.
7 Highlighting the importance of early detection,
the five-year survival rate of patients in the US with
operable early stage gastric cancer is 50%, but decreases to
< 10% in individuals with late stage disease.
8 Second,
conventional strategies for clinically treating these
conditions, usually involving a combination of surgery,
radiotherapy and chemotherapy, are far from optimal. In
gastric cancer, chemotherapy response rates can range for
20% for single agent therapies to 40% for combination
therapies,
9-11 and even if short-term responses are observed,
most tumors will eventually develop drug resistance and
relapse. The shortcomings of existing therapies for these
conditions has understandably fueled intense interest in the
use of so-called “targeted therapies”, which are antibody-
based or small-molecule drugs designed to selectively
inhibit particular oncogenes and oncogenic pathways, such
as HER2, EGFR, and the pro-angiogenic VEGF path-
ways.
12,13 Results from recent clinical trials evaluating these
drugs are starting to confirm that they can indeed convey a
significant, albeit modest, increase in overall survival and
lifespan when administered in combination with conven-
tional therapy.
14,15 Third, as we now argue in this review,
another likely reason for the high mortality rate of these
cancers is that these tumors are in reality highly hetero-
geneous, frequently differing between individual patients
in their fundamental biology and reliance on specific
cellular pathways. We will present a case for why consi-
dering cancer heterogeneity is likely to be important for
improving patient outcomes in these diseases, and describe
a variety of approaches currently being used to dissect
cancer heterogeneity and subclassify cancers at the
molecular level. For clarity, it is also important to note that
for this Review, the term “cancer heterogeneity” or “tumor
heterogeneity” will be used to refer to variations in tumors
between individual patients, and not to the populations of
different cell types within a given tumor ( e.g., cancer cells,
stromal cells, infiltrating immune cells, etc). 
An ample body of research over the past decade supports
the notion that many cancers are likely to display signifi-
cant variability at the clinical, histopathologic, and molecu-
lar level between individuals. For example, in non small
cell lung cancer (NSCLC) clinical trials evaluating the
EGFR inhibitor gefitinib, clinical responses were observed
only in a small proportion of patients.
16,17 The existence of
such ‘high-responder’ patient subpopulations provides
compelling evidence of clinical heterogeneity in NSCLC.
In terms of histopathology, tumors can also exhibit signifi-
cant differences in histologic architecture, tumor microen-
vironment, tumor grade and differentiation status. In sto-
mach cancer, it is well known that tumors can be subdivided
into at least two distinct histological types - an intestinal
variant where cancer cells develop as tubular structures
exhibiting features of well-differentated glandular tissue,
and a diffuse subtype where tumor cells are poorly differ-
entiated and spread along the lining of the stomach, some-
times resulting in the classical ‘linnitis plastica’ phenotype.
18
Such phenotypic variability logically suggests that different
biological programs are likely to be acting in individual
tumors, even when they are derived from the same target
organ. Reinforcing this notion, recent comprehensive
genomic analyses of lung, breast, and brain tumors have
confirmed that individual tumors can frequently exhibit
heterogeneous patterns of somatic mutations, gene amplifi-
cations and deletions, epigenetic profiles, and gene express-
ion portraits.
19-23
Given this remarkable heterogeneity however it is perhaps
surprising that with some notable exceptions (discussed
below) such patterns of variability are usually not consi-
dered in the specific management of cancer patients. Even
today, most clinical trials involving many of the major
solid cancers are still performed on unselected patient
populations without prior stratification.
24,25 However, the
ongoing identification of specific genes and proteins
playing important functional roles in cancer development
has recently led to advancements in the use of molecularly-
targeted assays to stratify and classify tumors. One good
example of a protein currently used for molecular strati-
fication in breast cancer is the estrogen receptor (ER).
Commonly measured by immunohistochemistry, overex-
pression of ER in breast tumors has been associated with
improved patient prognosis and less aggressive cancers.
26
Perhaps more importantly, ER expression is also used as a
predictive biomarker for treatment of breast cancer patients
with anti-hormonal therapies such as tamoxifen or aroma-
tase inhibitors.
27 At the genetic level, several assays are
now available to test for the presence of specific oncogenic
mutations in cancers. For example, in the afore-mentioned
lung cancer gefitinib trials, subsequent genetic analysis
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THE CONFOUNDING REALITY OF
CANCER HETEROGENEITY 
MOLECULAR APPROACHES FOR
CANCER STRATIFICATIONrevealed that patients exhibiting good responses to gefitinib
all exhibited tumor somatic mutations in the tyrosine
kinase domain of the EGFR gene.
28,29 Besides gene mutation,
oncogene dysregulation can also occur through the proces-
ses of genomic amplification and deletion. Such aberrations,
commonly detected either by techniques such as compa-
rative genomic hybridization (CGH or alternatively by
higher resolution array-CGH) or flouresence in-situ hybri-
dization (FISH), can involve a wide range of sizes ranging
from whole chromosomes and chromosomal arms, to
specific genes. Examples of chromosomal aberrations with
clinical significance include losses of chromosome 18q in
colon cancer, commonly associated with poor prognosis,
30
and gain of chromosome 8q in pancreatic cancer.
31 At the
single-gene level, high-level amplifications of the HER2
gene have been reported in 30% of breast tumors, identi-
fying a subtype of patients with particularly poor prog-
nosis.
32,33 Furthermore, with the development of anti-HER2
therapies such as traztuzamab (Herceptin), HER2 gene
amplification is also currently used as a predictive marker
for anti-HER therapy.
14,34
Besides conventional molecular platforms that typically
target only one or two genes/proteins at a time, newer
genomic approaches are also being evaluated with the
capability of stratifying cancers at the level of multiple
biomarkers. For example, gene expression profiles, where
the expression level of every single gene is measured
simultaneously, have been used to identify subclasses of
breast cancer.
35 An important finding enabled by this
technology has been the discovery that the expression
profiles of distinct breast cancer “molecular subtypes” (e.g.
ER positive and ER negative) differ not simply in their
expression of single genes like ER, but are in fact stri-
kingly different from one another at the level of hundreds
if not thousands of differentially expressed mRNA tran-
scripts.
36 The molecular distinctiveness of these subtypes is
consistent with proposals that these subtypes are indeed
distinct biological and clinical entities. This finding, which
has been replicated in several centers across the world
including ours, is just one example of how using genome-
wide information may provide greater accuracy and
insights than relying on single biomarkers alone.
37-39 More
recently, several groups have published reports describing
how global gene expression profiles can be computa-
tionally deconvoluted to provide information regarding the
activation levels of different oncogenic pathways in
tumors.
40,41 For example, by identifying gene expression
signatures associated with the activation of various onco-
genic pathways in vitro, Bild et al., were able to predict the
oncogenic status of these pathways in a variety of solid
tumors such as breast, lung and ovarian cancers.
40 Exci-
tingly, interpreting gene expression profiles in terms of
pathway activation patterns allows such information to be
readily linked to the selection of specific targeted therapies
designed to inhibit these pathways. Another advantage of
genomic assays is that they allow multiple pathways to be
interrogated without requiring multiple tests to be per-
formed, as would be the case in immunohistochemistry.
Such “high-throughput” pathway profiling could reveal
previously unanticipated interactions between different
pathways, and even suggest possible strategies for com-
bining different pathway inhibitors. Besides gene expres-
sion profiling, the introduction of newer deep-sequencing
technologies may also permit individual tumors to be
characterized at single-nucleotide resolution resolution,
which may provide further insights into the repertoire of
genetic aberrations and structural variations in solid
cancers.
42,43
While the availability of these molecular platforms renders
the ability to classify cancers technically feasible (i.e. “we
can do it”), it is perhaps worthwhile at this juncture to
formally consider why the practice of tumor stratification,
whereby heterogenous cancers are subdivided into clini-
cally and biologically homogenous groups, might be
useful for the improvement of caner patient outcomes (i.e.
“we should do it”). We believe that there are several reasons
why this might positively impact the clinical management
of cancer patients. First, the ability to stratify patients, at
the point of diagnosis, into either good or poor prognosis
categories might allow clinicians to personalize standard
therapeutic regimens for individual patients through dose-
escalation or dose-reduction. In the former (dose-escala-
tion), additional risks associated with the poor prognosis
status of the patient might justify the enhanced possibility
of adverse side effects caused by intensified therapy, while
in the latter (dose-reduction), a priori knowledge that the
patient may not require additional therapy might allow
clinicians to scale down treatments, thereby minimizing
toxic side effects, yet ultimately preserving the same level
of clinical benefit. A good example of how such prognostic
biomarkers might prove useful can be seen in the manage-
ment of patients with early stage breast cancer. Retrospec-
tive analyses has established that a certain proportion of
women with early stage breast cancer are likely to be
sufficiently treated with surgery only, requiring no further
adjuvant therapy.
44,45 However, without an assay capable of
pre-identifying these good prognosis patients, most early
stage breast cancer patients are treated by default with
adjuvant chemotherapy, and it has been estimated that at
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A CLINICAL ARGUMENT FOR TUMOR
STRATIFICATIONleast 70 - 80% of women with early stage breast cancer are
likely overtreated. To address this problem, researchers
from the US and Netherlands described in 2002 a 70-gene
expression signature capable of subclassify such early
stage breast cancer patients into good and bad prognosis
categories respectively.
46 Since then, the testing of this 70-
gene signature has undergone extensive independent
validation and is now the subject of a major European
clinical trial (MINDACT, see below).
47,48
A second reason for the importance of tumor stratifi-
cation involves the prediction of response to specific thera-
pies (predictive biomarkers). While we have already cited
examples where tumors with specific genetic features have
been shown to respond to particular therapies, such as
EGFR mutations and EGFR inhibitors, or HER2 gene
amplifications and traztuzamab, it should be noted that
these cases likely represent only the fortuitous minority
where the predictive biomarker corresponds to the drug
target itself (e.g. trastuzamab and HER2). In many other
cases, identification of the relevant predictive biomarker
may not be so clear cut. For example, it has been reported
that tumors with mutations in the B-RAF gene may impart
sensitivity to MEK inhibitors,
49 or that mutations that cons-
titutively activate the RAS oncogene may impart sensi-
tivity to histone deactylating agents.
50 Besides biomarkers
that predict drug sensitivity, there also exists a separate
class of mutations in particular oncogenes that impart drug
resistance. Examples of such “anti-predictive” factors
include the lack of efficacy of EGFR inhibitors in colon
cancers with k-ras mutations,
51 and resistance to traztu-
zamab in HER2-amplified breast cancers with concomi-
tant activation of the PI3K pathway.
52 Beyond targeted
therapies, several predictive biomarkers for conventional
cytotoxic agents have also been proposed, such as mutated
β-tubulin for taxanes and TS for 5-FU.
53,54
A third important justification for the implementation of
tumor stratification is that it maximizes the opportunity for
therapeutic benefits to be observed, particularly in the con-
duct of clinical trials evaluating novel therapies. Analyses
by the pharmaceutical industry of current drug trials have
revealed that most anti-cancer drugs typically fail during
late stage evaluation (i.e. Phase II or III) typically due to
lack of detectable efficacy or toxicity.
55 However, because
such trials are typically performed in unselected patient
populations, it is quite possible that certain drugs may elicit
dramatic responses in a small population of patients, but
that this beneficial effect may be diluted when such patients
are intermixed with the larger population. Indeed, drugs
such as herceptin and gefitinib would likely have not been
approved if tested in an unselected set of cancer patients.
Thus, examples such as these provide a strong motivation
for the practice of tumor stratification in the management
and evaluation of cancer patients.
56
One example of a major cancer type where patient outcomes
have been significantly impacted by molecular stratification
has been childhood acute lymphoblastic leukemia (cALL).
Prior to 1972, cALL was largely regarded and treated as a
“single disease”, with a dismal cure rate of only 5%.
57 Since
that time, however, progress in cytogenetic and molecular
technologies has revealed that cALL is in fact a hetero-
gen eous collection of distinct diseases.
58 Through detailed
comparisons of individual cALLs with their normal
counterparts in the hierarchy of hematopoietic development,
we now know that distinct subtypes of cALL are likely to
originate from blood progenitor cells originally committed to
differentiate via a T or B-cell lineage, but in cALL these
progenitor cells have acquired mutations causing both
deregulated cell proliferation and stage-specific developmental
arrest.
59 Currently, cALLs are classified into at least seven
distinct subgroups, with each subgroup being either
associated with a particular stage of hematopoietic
differentiation or a specific cytogenetic aberration such as
hyperdiploidy or signature chromosomal translocations
including TEL-AML1 (otherwise known at ETV6-RUNX1)
or BCR-ABL.
60 Importantly, supporting the notion that these
cALL subtypes are likely to represent distinct biological
entities, in a large series of hundreds of cALL patients
followed up over 15 years, it has been established that each
of these subtypes is associated with a distinct course of
disease progression.
58 For example, patients having TEL-
AML1 or E2A-PBX1 fusions are more likely to exhibit
relatively favorable clinical outcomes compared to patients
with BCR-ABL or MLL-AF4 fusions. The biological
distinctiveness of these subgroups has also been further
supported by genome-wide gene expression profiling studies,
confirming that the different cALL subtypes are each
associated with characteristic patterns of gene expression.
61,62
Knowledge regarding the existence of these cALL
subtypes has revolutionized treatment for cALL in several
ways. First, it permitted clinicians to adapt and modify
standard therapy regimens, once used to treat all cALLs,
specifically to the different subtypes. For example, while
most cALL cases are treated with a three phase regimen of
remission-induction, intensification/consolidation, and
continuation therapy, patients with mature B-cell ALL are
further treated with short-term intensive chemotherapy,
63, 64
while patients with T-Cell ALLs commonly are addition-
ally treated with cyclophosphamide and asparagine during
the remission induction phase.
65 Second, knowledge of the
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IMPACT OF CANCER HETEROGENEITY 
- THE EXAMPLE OF CHILDHOOD ALLspecific molecular aberrations in each subtype allowed
drug discovery efforts to focus on these aberrations as
potential pharmacologic targets. This is best seen in BCR-
ABL positive cALL, a subtype that has traditionally been
associated with very poor prognosis.
66 However, with the
development of imatinib mesilate, a small molecule inhibi-
tor of the ABL kinase, there is now an effective treatment
for BCR-ABL positive cALL, with initial response rates
being close to 100% in this specific subgroup of cALL.
67
Through the tailoring of generic regiments and the availa-
bility of subtype specific targeted therapies, the cure rate
today for childhood ALL exceeds 80%. 
While cALL remains a powerful testament to the utility
of tumor stratification, the impressive advances in our
ability to manage cALL, however, should not be taken as a
sign that this disease has been truly conquered. There is
still a significant fraction of cALL patients (20%) who are
not cured with existing therapies, and our ability to manage
ALL in older patients in still far from optimal.
66 One
possible reason is that additional genetic and molecular
heterogeneity may exist in this disease that has previously
been undetected, and that further genetic subdivisions will
be required to further differentiate between these various
seven subclasses. Fortunately, more comprehensive and
high resolution technologies are now available that are
capable of identifying genetic and epigenetic aberrations
on a genome wide scale. For example, a recent genome
wide SNP analysis of ALLs associated with B-cell pheno-
types identified several mutations, deletions, and structural
rearrangements in various regulators of B-cell development,
such as PAX5 and TCF3.
68 Future work will then allow
ALL treatments to be individualized to the specific genetic
makeup of each tumor cell. 
In contrast to the hematopoietic malignancies, similar
attempts to stratify many of the major solid cancers such as
lung, gastric, and liver cancer have been hampered by
many challenges. One major difficulty is that solid tumors
are often typically characterized by highly aberrant chro-
mosomal karyotypes that are considerably more complex
than those observed in the hematopoetic malignancies.
69
With few exceptions, the heightened complexity of solid
tumor karyotypes has thwarted attempts by conventional
cytogenetics to identify signature aberrations associated
with different solid tumor subtypes; for example, recurrent
chromosomal translocations that may produce important
fusion genes and transcripts. Indeed, it is only in the past
few years that recurrent fusion genes such as TMPRSS2-
ERG and EML4-ALK in solid tumors have been identified
in prostate and lung cancer, respectively.
70,71 In both these
cases, these fusion genes were not identified through
conventional chromosomal cytogenetics, but through inno-
vative high-resolution genomic approaches. Nevertheless,
these examples provide important proof that recurrent
fusion transcripts do indeed exist in solid tumors, and it is
expected that identification of novel fusion genes will
continue, particularly with the use of next-generation deep
sequencing methods.
72
Besides increased chromosomal complexity, a second
challenge faced in the molecular stratification of solid
tumors lies in the traditional reliance of diagnostic plat-
forms such as immunohistochemistry or gene sequencing
that typically measure single biomakers (either genes or
proteins). While such techniques are amenable to the
detection of highly recurrent aberrations, recent large scale
comprehensive sequencing analysis of various solid cancers,
including pancreatic, brain, breast and colon cancers, has
demonstrated that many solid tumors are likely to have a
preponderance of mutations in multiple genes with low
rates of recurrence.
22,73,74 However, when such genes are
grouped together by their respective pathways of activation,
analysis has shown that such mutations tend to target a
series of common core signaling pathways.
73,75 These find-
ings suggest that these oncogenic pathway, rather than the
gene itself, is likely to represent the unit of mutational
selection in solid cancers. Thus, the molecular stratification
of these cancers will require analytical platforms that can
measure multiple genes simultaneously, rather than one
gene or protein at a time. Unfortunately, the expense and
complexity of such genomic platforms are still prohibi-
tively expensive and insufficiently robust to validate their
regular use in clinical practice. 
A third issue of complexity facing the molecular stratifi-
cation of solid tumors is that unlike blood disorders, solid
tumors comprise a diverse mix of many different cell types
including cancer cells, stromal cells, infiltrating immune
cells, and endothelial vasculature.
76 Recent evidence has
shown that in many cases, disease progression and treat-
ment response for many solid tumors likely involve a
combination of interactions between these different cell
types. For example, studies in experimental models have
shown that tumor-associated fibroblasts, while non-
malignant in their genetic makeup, can play a profound
role in the overall rate of tumor growth,
77 and studies have
shown that colon cancer disease prognosis can be affected
either by the rate of immune cells,
78 or by the presence of
tumor stroma.
79 The necessity to consider interactions
between such entities raises another level of complexity
that is overtly less of an issue in the blood disorders, which
are commonly thought of as clonal diseases.
Patrick Tan
Yonsei Med J   http://www.eymj.org    Volume 50   Number 4   August 2009 468
CHALLENGES FOR THE MOLECULAR
STRATIFICATION OF SOLID TUMORSBesides the biological challenges of increased genomic
complexity, pathway directed mutational profiles, and inter-
actions with various cell types, it is also worth noting that a
number of practical and logistic issues have also chal-
lenged research into the molecular stratification of solid
tumors. Most solid tumors are collected through some
invasive means such as surgery or biopsy, and so analysis
of these tumors is limited only in clinical scenarios where
such invasive procedures are an option. In the case of
NSCLC, since late stage lung tumors are not treated with
surgery, our knowledge of the molecular factors at play in
late stage NSCLC is still relatively poor, despite the major-
ity of NSCLC patients being diagnosed with advanced
inoperable disease.
80 In such cases, samples are typically
limited to material through diagnostic methods such as
fine-needle aspiration (FNAs), which has led some inves-
tigators to devise novel ways to analyze such so-called
‘low-volume’ samples.
81,82 The challenge of obtaining large
numbers of surgical samples has also impeded the estab-
lishment of large-scale molecular databases of these cancers
to definitely establish overall levels of molecular diversity
for many tumor types. Addressing this problem has required
the formation of large multi-center consortia, or the devel-
opment of novel statistical meta-analysis protocols to
combine genomic data from multiple data sets to identify
conserved molecular patterns.
83,84
Despite these significant challenges, progress is indeed
being made towards the molecular stratification of solid
cancers. One obvious example of a major solid cancer
where attempts at molecular stratification are showing
progress is carcinoma of the breast. As mentioned above,
breast cancers are already routinely subdivided into ER-
positive and ER-negative subtypes, which are associated
with distinct prognosis and responses to anti-hormonal
treatment. Another important subtype of breast cancer for
which routine testing is performed are tumors that overex-
press the HER2 growth factor receptor, as such tumors can
be targeted with traztuzamab. In addition to these three
well-recognized subgroups, results from more comprehen-
sive expression profiling analysis has also revealed the
existence of further subgroups. For example, it is now clear
that ER+ tumors sometimes called “luminal” tumors,
reflecting the fact that they are likely to arise from luminal
cells in the mammary epithelium) can be further subdivided
into two more subtypes - Luminal A and Luminal B, that
show very distinct patterns of patient prognosis.
35,85 Geno-
mic signatures have also been identified that can predict
the mutational status of important cancer genes such as
p53 in breast cancer,
86 and evidence is further emerging
that these breast cancer subtypes could also exhibit distinct
responses to various forms of conventional cytotoxic the-
rapy as well as targeted therapies such as MEK inhibi-
tors.
87,88 Besides subtypes based solely on gene expression
patterns, recent work has also demonstrated that combin-
ing gene expression-based subtypes with DNA copy
number information can further subdivide patients into
even more homogenous populations.
89 Such “integrative
genomic” analyses will likely be required to address the
rampant genomic complexity of solid tumors. 
In contrast to breast cancer, consensus regarding specific
molecular subtypes in many other solid tumors has yet to
gain general acceptance. In our own specific research area
of gastric cancer, several distinct molecular subtypes of
gastric cancer have been reported, and correlative analysis
of these subtypes to clinical information has identified
expression signatures associated with differing histological
subtypes and in some cases prognosis.
90,91 However, few of
these genomic predictors have been independently
validated in reasonably large independent patient cohorts,
and attempts at validation are confounded by differences in
the patient populations from different countries and centres,
including differences in treatment protocol. Furthermore,
with the increasing number of genomic biomarkers linked
to cell lineage, drug sensitivity and pathway activation
status reported in the literature, there is also the oft-cited
concern that different studies ostensibly targeting the same
biological phenotype (e.g. prognosis in early stage breast
cancer) tend to identify non-overlapping signatures.
92-95
Such concerns, however, should be evaluated in the light
of recent studies showing that apparently ‘distinct’ signa-
tures tend to nevertheless target the subpopulations of
tumors, and that consensus can be ultimately established
through the rigorous cross-comparison of different data
sets, as has recently been demonstrated for breast cancer
and NSCLC.
48,96 Ultimately, the acid test for the clinical
robustness of such stratifications will have to occur in the
form of well-designed randomized prospective control
trails designed to robustly test the actual clinical utility of
such proposed schema. In fact, there are already several
trials that are already underway or being proposed. For
example, the MINDACT trial involves the recruitment of
6,000 women across multiple centers with early stage
breast cancer whose treatment will depend upon their exp-
ression profiles of the 70-gene prognostic classifier describ-
ed above.
97 Another exciting series of trials involves the
use of genomic signatures to guide chemotherapy treatment
in early-stage lung cancer.
98 This is another clinically
challenging disease where the standards of chemotherapy
have not been established, and thus treatment of NSCLC
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PROGRESS IN THE MOLECULAR
STRATIFICATION OF SOLID CANCERSpatients is largely due to physician preference. Results
from these trials will definitely establish if genomic
technologies are at the stage where they are sufficiently
robust and reproducible for the information to be inter-
preted in such a fashion that they actually guide clinical
treatment. 
We close this review with a brief survey of some antici-
pated future challenges facing clinicians and researchers
interested in the molecular stratification of cancer. With
the increasing ability to characterize tumors at multiple
levels including mutations, expression signatures, copy
number aberrations, and epigenetic profiles, it will be criti-
cal to develop robust analytical systems whereby such
multi-dimensional data can be integrated, even possibly
with host genotype information, to define robust biological
subtypes of cancer. Analysis of the independence and
relationship between different genetic aberrations, such as
the mutual exclusivity of EGFR and k-ras mutations in
lung cancer,
99 could also prove very useful in delineating
major oncogenic signaling pathways and their sub-
components in primary tumors. Another challenge arising
from the notion that most, if not all, cancers comprise
multiple subtypes is how to transform currently existing
drug discovery programs, that traditionally have focused
on identifying single drugs with efficacy in the majority of
cancers, to identifying many drugs targeted for distinct
cancer subtypes, in a rapid and cost-efficient manner. A
third challenge arises when one considers that many of
these studies have relied upon the molecular analysis of
tumors, which can only be obtained through invasive means
such as surgery or biopsies. It would be exciting to assess
if similar patterns of cancer stratification could be inferred
using profiles derived from more easily obtainable body
fluids from cancer patients such as blood or stool. Finally,
one also needs to grapple with recent findings suggesting
that there exists in tumors a rare stem cell-like population
that can prove highly drug resistant.
100 Techniques to detect
and classify such cancer stem cells will represent a key
challenge in cancer classification, and success in doing so
may represent the pivotal shift in our ability to treat cancer
in a way that tangibly affects overall cancer outcomes. 
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